1. Piffko A, Uhl C, Vajkoczy P, Czabanka M, Broggini T. EphrinB2-EphB4 Signaling
in Neurooncological Disease. Int J Mol Sci. 2022 Jan 31;23(3):1679. doi:
10.3390/ijms23031679. PMID: 35163601; PMCID: PMC8836162.
2. Liu X, Wang K, Hou S, Jiang Q, Ma C, Zhao Q, Kong L, Chen J, Wang Z, Zhang H,
Yuan T, Li Y, Huan Y, Shen Z, Hu Z, Huang Z, Cui B, Li P. Insulin induces
insulin receptor degradation in the liver through EphB4. Nat Metab. 2022
Sep;4(9):1202-1213. doi: 10.1038/s42255-022-00634-5. Epub 2022 Sep 21. PMID:
36131205..
3. Bhatia S, Nguyen D, Darragh LB, Van Court B, Sharma J, Knitz MW, Piper M,
Bukkapatnam S, Gadwa J, Bickett TE, Bhuvane S, Corbo S, Wu B, Lee Y, Fujita M,
Joshi M, Heasley LE, Ferris RL, Rodriguez O, Albanese C, Kapoor M, Pasquale EB,
Karam SD. EphB4 and ephrinB2 act in opposition in the head and neck tumor
microenvironment. Nat Commun. 2022 Jun 20;13(1):3535. doi:
10.1038/s41467-022-31124-7. PMID: 35725568; PMCID: PMC9209511.